141
Туржанова и др. // Проблемы биологии и медицины». – 2021. – №5.1 (131). –
С.190-195.
39.Флуороцентная диагностика кожных метастазов рака молочной железы:
Методические рекомендации / В.В. Бенберин, Н.А. Шаназаров, Р.И. Рахимжанова
и др. - Нур-Султан, 2021. – 30 с.
40.Фотодинамическая терапия кожных метастазов рака молочной железы:
методические рекомендации / В.В. Бенберин, Н.А. Шаназаров, Р.И. Рахимжанова
и др. – Нур-Султан, 2021. – С. 38 с.
41.Ходорович, О.С. Наследственная форма рака молочной железы. Методы профилактики / О.С. Ходорович // Вестник Российского научного центра рентгенорадиологии Минздрава России. – 2012. – Вып. 12. – Т. 2. – С. 4.
42.Эпидемиологические аспекты заболеваемости и смертности по раку молочной железы в городе Нур-Султан / Е.И. Жаппаров, Н.А. Шаназаров, М.Е. Тулеутаев и др. // Тезисы докладов XI Съезда онкологов и радиологов стран СНГ и Евразии. - Казань, 23-25.04.2020. - С. 399-400.
43.Эффективность фотодинамической терапии в паллиативном лечении прогрессирующего рака молочной железы с местным продолженным ростом / Н.А. Шаназаров, В.В. Бенберин, Р.И. Рахижманова и др. // Материалы VIII Петербургского международного онкологического форума «Белые ночи 2022». Приложение.– 2022. – Т. 68 (№3). - С. 297-298.
44.11 years' follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA)
trial / D. Cameron, M.J. Piccart Gebhart, R.D. Gelber et al. // The Lancet. - 2017 – V.
389 (10075). – P. 1195–1205.
45.3'-UTR Polymorphisms in the MiRNA machinery genes DROSHA, DICER1, RAN, and XPO5 are associated with colorectal cancer risk in a Korean population / S. Cho, J. Ko, J. Kim et al. // PLoS One. - 2015. doi:10.1371/journal. pone.0131125.
46.A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase / P. Frosst, H.J. Blom, R. Milos et al. // Nat. Genet.
– 1995. – V. 10. – P. 111-113.
142
47. A common coding variant in CASP8 is associated with breast cancer risk / A. Cox, A.M. Dunning, M. Garcia-Closas et al. // Nature. Gen. – 2007. – V. 39. – P. 352– 358.
48.A common functional polymorphism (C-->A substitution at position −863) in the promoter region of the tumor necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha / T. Skoog, F.M. Van't Hooft, B. Kallin et al. // Hum. Mol. Genet. – 1999. – V. 8 (8). – P. 1443-1449.
49.A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) / G. Thomas, K. Jacobs, P. Kraft et al. // Nat. Genet. – 2009. – V. 41. – P. 579–584.
50.A new genome-driven integrated classification of breast cancer and its implications / S.J. Dawson, O.M. Rueda, S. Aparicio et al. // EMBO. J. – 2013. – V. 32.
– P. 617-628.
51.A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer / N. Bogdanova, C. Cybulski, M. Bermisheva et al. // Breast. Cancer. Res. Treat. - 2009. - V. 118. - P. 207-211.
52.A Novel Functional TagSNP Rs7560488 in the DNMT3A1 Promoter Is Associated with Susceptibility to Gastric Cancer by Modulating Promoter Activity / H. Wu, K. Zhang, P. Gong et al. // PLoS ONE. – 2014. – V. 9. – P. e92911.
53.A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer / H. Shen, L. Wang, M.R. Spitz et al. // Cancer. Res. – 2002. – V. 62. – P. 4992-4995.
54.A role for yeast and human translesion synthesis DNA polymerases in promoting replication through 3-methyl adenine / R.E. Johnson S.L. Yu, S. Prakash, L. Prakash // Mol. Cell. Biol. – 2007. - V. 27 (20). – P. 7198-205.
55.A single-nucleotide polymorphism in the 3′-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer / W. Wang, P. Yuan, D. Yu et al. // Oncotarget. – 2016. - V. 7 (14). – P. 18984–18998.
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/
143
56.Accuracy of hereditary diffuse gastric cancer testing criteria and outcomes in patients with a germline mutation in CDH1 / R.S. van der Post, I.P. Vogelaar, P. Manders et al. // Gastroenterology. – 2015. – V. 149 (4). – P. 897 906.e819.
57.Apostolou, P. Hereditary breast cancer: the era of new susceptibility genes / P. Apostolou, F. Fostira // Biomed. Res. Int. - 2013. - V. 2013. - Article ID 747318.
58.Association between ERCC5 gene polymorphisms and breast cancer risk / Nari Na, Eer Dun, Lidong Ren, Guoxin Li. // Int. J. Clin. Exp. Pathol. – 2015. – V. 8 (3). – P. 3192–3197.
59.Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects / P.H. Lu, J. Yang, C. Li et al. // Breast Cancer Res. Treat. - 2011. - V. 126. - P. 663-670.
60.Association of a LSP1 gene rs3817198T>C polymorphism with breast cancer risk: evidence from 33,920 cases and 35,671 controls / M.B. Chen, C. Li, W.X. Shen et al. // Mol. Biol. Rep. - 2010. - V. 38. - P. 4687-4695.
61.Association of two mutations in the CHEK2 gene with breast cancer / N. Bogdanova, N. Enssen-Dubrowinskaja, S. Feshchenko et al. // Int. J. Cancer. - 2005. - V. 116. - P. 263-266.
62.ATM has a major role in the double strand break repair pathway dysregulation in
sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels / S. Rondeau, S. Vacher, L. De Koning et al. // Br. J. Cancer. – 2015. – V. 112 (6). – P. 1059–1066.
63. Begam, N. Promoter hypermethylation of the ATM gene as a novel biomarker for breast cancer / N. Begam, K. Jamil, S.G. Raju // Asian. Pac. J. Cancer. Prev. - 2017. – V. 18 (11). – P. 3003–3009.
64.Biomarkers in molecular medicine: cancer detection and diagnosis / P. Maruvada, W. Wang, P.D. Wagner, S. Srivastava // BioTechniques. – 2005. – V. 38 (4S). - P. S9S15.
65.Blumenthal, G.M. PTEN hamartoma tumor syndromes / G.M. Blumenthal, P.A. Dennis // Europ. J. Hum. Genet. - 2008. - V. 16. - P. 1289-1300.
144
66.Breast cancer in patients with gene polymorphisms associated with metabolic syndrome / N.K. Seidalin, V.V. Benberin, N.A. Shanazarov et al. // Systematic Reviews in Pharmacy. – 2020. – V. 11, Issue 11. - Р. 1126-1129.
67.Breast cancer risk associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression / R. Cowper Sallari, X. Zhang, J.B. Wright et al. //
Nature. Genetics. – 2012. – V. 44 (11). – P. 1191–1198.
68.C6ORF97 ESR1 breast cancer susceptibility locus: Influence on progression and
survival in breast cancer patients / M. Yamamoto Ibusuki, Y. Yamamoto, S. Fujiwara et al. // European J. of Human Genetics. – 2015. – V. 23 (7). – P.949.
69. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 / J. Ferlay, I. Soerjomataram, R. Dikshit et al. // Int. J. Cancer. – 2015. – V. 136 (5). – P. E359 386.
70.Canisius, S. A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence / S. Canisius, J.W.M. Martens, L.F.A. Wessels // Genome Biol. – 2016. – V. 17. – P.261.
71.CHEK2-breast cancer consortium: low-penetrance susceptibility to breast cancer due to CHEK2(*)1 lOOdelC in noncarriers of BRCA1 or BRCA2 mutations / H. Meijers-Heijboer, A. van den Ouweland, J. Klijn et al. // Nat. Genet. - 2002. – V. 31. - P. 55-59.
72.Chundi Gao SNP mutation related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database / Chundi Gao, Jing Zhuang, Chao Zhou et al. // Cancer. Med. – 2019. - V. 8 (5). – P. 2303–2312.
73.Circadian gene variants and breast cancer / E. Reszka, M. Przybek, O. Muurlink, B. Peplonska // Cancer Lett. – 2017. – V. 390. – P. 137–145.
74.Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer / D.P. Atchley, C.T. Albarracin, A. Lopez et al. // J. Clin. Oncol. – 2008. – V. 26. - P. 4282–4288.
75.Clonal evolution in breast cancer revealed by single nucleus genome sequencing / Y. Wang, J. Waters, M.L. Leung et al. // Nature. – 2014. – V. 512. – P. 155-160.
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/
145
76.Common genetic polymorphisms of microRNA biogenesis pathway genes and risk of breast cancer: a case-control study in Korea / H. Sung, K.M. Lee, J.Y. Choi et al. // Breast .Cancer .Res. Treat. - 2011. - V. 130. P. 939–951.
77.Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer / S.N. Stacey, A. Manolescu, P. Sulem et al. // Nat. Genet. – 2007. – V. 39. – P. 865–9.
78.Complexity in regulation of microRNA machinery components in invasive breast carcinoma / S. Kwon, J. Lee, B. Kim et al. // Pathol. Oncol. Res. - 2014. - V. 20. - Р. 697–705.
79.Comprehensive molecular portraits of human breast tumours / D. Koboldt, M.D. McLellan, H. Schmidt et al. // Nature. – 2012. – V. 490 (7418). – P. 61 70.
80.Cooperberg, M.R. Active surveillance for prostate cancer: progress and promise / M.R. Cooperberg, P.R. Carroll, L. Klotz // J. Clin. Oncol. – 2011. – V. 29 (27). – P. 3669–3676.
81.COSMIC: exploring the world's knowledge of somatic mutations in human cancer / S.A. Forbes, D. Beare, P. Gunasekaran et al. // Nucleic. Acids. Res. – 2015. –
V. 43 (Database issue):D805–D811.
82. Couch, F.J. Two decades after BRCA: Setting paradigms in personalized cancer care and prevention / F.J. Couch, K.L. Nathanson, K. Offit // Science. – 2014. – V. 343.
– P. 1466-470.
83.Cybulski, C. Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin / C. Cybulski // Hered. Cancer Clin. Pract. - 2007. - V. 5. - P. 164-179.
84.Database resources of the National Center for Biotechnology Information / D.L. Wheeler, T. Barrett, D.A. Benson et al. // Nucleic Acids Res. -2007. – V. 35 (suppl_1).
– P. D5-12.
85. Detecting Somatic Mutations in Normal Cells / Y. Dou, H.D. Gold, L.J. Luquette,
P.J. Park // Trends. Genet. – 2018. – V. 34 (7):545-557.
146
86.Diverse signaling pathways modulate nuclear receptor recruitment of N CoR and
SMRT complexes / R.M. Lavinsky, K. Jepsen, T. Heinzel et al. // Proc. Natl. Acad. Sci.
USA. – 1998. – V. 95 (6). – P. 2920 2925.
87.DNA damage and breast cancer risk / T.R. Smith, M.S. Miller, K.K. Lohman et al. // Carcinogenesis. – 2003. – V. 24 (5). – P. 883 889.
88.EAU guidelines on prostate cancer / A. Heidenreich, G. Aus, M. Bolla et al. // European. Urology. – 2008. – V. 53. – P. 31–45.
89.Economopoulou, P. Beyond BRCA: New hereditary breast cancer susceptibility genes / P. Economopoulou, G. Dimitriadis, A. Psyrri // Cancer Treatment. – 2015. – V.
41.– P. 1-8.
90.Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations / H. Nechushtan, T. Hamburger, S. Mendelson et al. // BMC Cancer. – 2009. – V. 9. – P. 60. Published online 2009. – V.
18.doi:10.1186/1471-24 07-9-60. PMCID: PMC2667534
91.Emerging landscape of oncogenic signatures across human cancers / G. Ciriello, M.L. Miller, B.A. Aksoy et al. // Nat. Genet. – 2013. – V. 45. – P. 1127–1133.
92.Epidemiologic risk factors for in situ and invasive breast cancers among postmenopausal women in the National Institutes of Health-AARP diet and health study / M. Mullooly, Z.G. Khodr, C.M. Dallal et al. // Am. J. Epidemiol. - 2017. -V. 186 (12). - P.1329-1340.
93.Essential role for nuclear PTEN in maintaining chromosomal integrity / W.H. Shen, A.S. Balajee, J. Wang et al. // Cell. – 2007. – V. 128 (1). – P. 157 170.
94.European perspective for effective cancer drug development / D. Lacombe, S. Tejpar, R. Salgado et al. // Nat. Rev. Clin. Oncol. – 2014. – V. 11. – P. 492-498.
95.Evaluation of genetic variants in MicroRNA biosynthesis genes and risk of breast cancer in Chinese women / Y. Jiang, J. Chen, J. Wu et al. // Int. J. Cancer. - 2013. - V.
133.- P. 2216–2224.
96.Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men / R.J.
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/
147
Klein, C. Hallden, A. Gupta et al. // European. Urology. - 2012. – V. 61 (3). – P.471-
477.
97.Evaluation of targeted therapies in advanced breast cancer: The need for largescale molecular screening and transformative clinical trial designs / Z. Fadoukhair, D. Zardavas, M.A. Chad et al. // Oncogene. – 2016. – V. 35. – P. 1743-1749.
98.Evidences of Polymorphism Associated with Circadian System and Risk of Pathologies: A Review of the Literature / F.J. Valenzuela, J. Vera, C. Venegas et al. // Int. J. Endocrinol. – 2016. – V. 2016. – P. 12. doi.org/10.1155/2016/2746909
99.Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen / I. Girault, F. Lerebours, S. Amarir et al. // Clin. Cancer. Res. – 2003. – V. 9 (4). – P. 1259 1266.
100.Founder mutations in BRCA1 and BRCA2 genes / R. Ferla, V. Calô, S. Cascio et al. // Ann. Oncol. - 2007. - V. 18. - P. 93-98.
101.Functional germline variants as potential co-oncogenes / D. Agarwal, С. Nowak, N.R. Zhang, L. Pusztai, C. Hatzis // NPJ. Breast. Cancer. - 2017. – V. 3. – P. 46.
102.GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis /
A.B. Dydensborg, A.A. Rose, B.J. Wilson et al. // Oncogene. – 2009. – V. 28 (29). – P.
2634 2642.
103. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin 5 (XPO5) in breast tumorigenesis / D. Leaderer, A.E. Hoffman, T. Zheng et al. // Int. J. Mol. Epidemiol. Genet. - 2011. - V. 2. - Р. 9-18.
104. Genetic and epigenetic regulation of TOX3 expression in breast cancer / Y. J.
Han, J. Zhang, Y. Zheng et al. // PLoS. ONE. – 2016. - V. 11 (11). - e0165559 10.1371/journal.pone.0165559.
105.Genetic breast cancer susceptibility variants and prognosis in the prospectively randomized success a study / A. Hein, B. Rack, L. Li et al. // Geburtshilfe und Frauenheilkunde. – 2017. – V. 77 (6). – P. 651–659.
106.Genetic correction of PSA values using sequence variants associated with PSA levels / J. Gudmundsson, S. Besenbacher, P. Sulem et al. // Science. Translational. Medicine. - 2010. – V. 2 (62). – P. 62ra92.
148
107.Genetic polymorphism in ERCC5 and breast cancer risk / Saima Shakil Malik, Sumaira Mubarik, Mehreen Baig et al. // Mol. Biol. Res. Commun. - 2019. – V. 8 (1). - P. 27-31.
108.Genetic polymorphisms and breast cancer risk: evidence from metaanalyses, pooled analyses, and genome-wide association studies / S. Peng, В. Lti, W. Ruan et al. // Breast. Cancer. Res. Treat. - 2011. - V. 127. - P. 309-324.
109.Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response / D. Liang, L. Meyer, D.W. Chang et al. // Cancer Res. - 2010. - V. 70. - P. 9765–9776.
110.Genetic variants in RNA-induced silencing complex genes and prostate cancer /
Z. Nikolić, D. Pavicević, N. Vućić et al. // World. J. Urol. - 2016. doi: 10.1007/s00345-
016-1917-0.
111.Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. / W. Zheng, J. Long, Y.T. Gao et al. // Nat. Genet. - 2009. – V. 41 (3). - P. 324-328.
112.Genome-wide association study identifies novel breast cancer susceptibility loci / D.F. Easton, K.A. Pooley, A.M. Dunning et al. // Nature. - 2007. - V. 447. - P. 10871093.
113.Germline 657del5 mutation in the NBS1 gene in breast cancer patients / В. Gorski, Т. Debniak, B. Masojc et al. // Int. J. Cancer. - 2003. - V. 106. - P. 379-81.
114.Goodman S.R. Goodman's Medical Cell Biology (Fourth Edition) / S.R. Goodman.- London: Academic Press, 2020. – 407 с.
115.Gregory, R.I. MicroRNA biogenesis: isolation and characterization of the microprocessor complex / R.I. Gregory, T.P. Chendrimada, R. Shiekhattar // Meth. Mol. Biol. - 2006. - V. 342. - P. 33–47.
116.Hanahan, D. Hallmarks of Cancer: The Next Generation / D. Hanahan, R.A. Weinberg // Cell. – 2018. – V. 144 (5) – P. 646 – 674.
117.Hanahan, D. Hallmarks of cancer: the next generation / D. Hanahan, R.A. Weinberg // Cell. – 2011. – V. 144 (5). – P. 646 674.
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/
149
118.Hankinson, S.E. Towards an integrated mod breast cancer etiology. The lifelong interplay of genes, lifestyle, and hormones / S.E. Hankinson, G.A. Colditz, W.C. Willett // Breast. Cancer. Res. - 2004. - V. 6. – P. 213-218.
119.Hata, A. Dysregulation of microRNA biogenesis machinery in cancer / A. Hata, R. Kashima // Crit. Rev. Biochem. Mol. Biol. - 2016. - V. 51. - Р. 121–134.
120.Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins / A. Bansal, D.K. Murray, J.T. Wu et al. // The Journal of Clinical Endocrinology & Metabolism. - 2000. - V.85 (3). – P. 1272–1276.
121.High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations / M.G. Van Lier, A. Wagner, E.M. Mathus-Vliegen et al. // Am. J. Gastroenterol. - 2010. - V. 105. - P. 1258-1264.
122.High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia / A.P. Sokolenko, A.G. Iyevleva, E.V. Preobrazhenskaya et al. // Int. J. Cancer. - 2012. - V. 130. - P. 2867-2873.
123.Hollander, M.C. PTEN loss in the continuum of common cancers, rare syndromes and mouse models / M.C. Hollander, G.M. Blumenthal, P.A. Dennis // Nat. Rev. Cancer. – 2011. – V. 11 (4). – P. 289 301.
124.How many etiological subtypes of breast cancer: Two, three, four, or more? / W.F. Anderson, P.S. Rosenberg, A. Prat et al. // J. Natl. Cancer. Inst. - 2014. – V. 106. –
P. : dju165.
125.Huang, Y.T. Joint Analysis of SNP and Gene Expression data in genetic association studies of complex diseases / Y.T. Huang, T.J. VanderWeele, X. Lin // Ann. Appl Stat. – 2014. – V. 8. – P. 352–376.
126.Impact of deleterious passenger mutations on cancer progression / C.D. McFarland, K.S. Korolev, G.V. Kryukov et al. // Proc. Natl. Acad. Sci. USA. – 2013. –
V. 110. – P. 2910-2915.
127. Impact of polymorphisms in microRNA biogenesis genes on colon cancer risk and microRNA expression levels: a population based, case-control study / L.E. Mullany, J.S. Herrick, R.K. Wolff et al. // BMC Med. Genomics. - 2016. - V. 9. - Р. 21. doi: 10.1186/s12920-016-0181-x.
150
128.Impaired microRNA processing enhances cellular transformation and tumorigenesis / M.S. Kumar, J. Lu, K.L. Mercer et al. // Nat. Genet. - 2007. - V. 39. - P. 673–677.
129.Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity / V. Almendro, Y.K. Cheng, A. Randles et al. // Cell. Reports. – 2014. – V. 6. – P. 514-527.
130.Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families / В. Newman, M.A. Austin, M. Lee, M.C. King // Proc. Natl. Acad. Sci. USA. - 1988. - V. 85. - P. 3044-3048.
131.Integrative analysis of RNA polymerase II and transcriptional dynamics upon MYC activation / S. de Pretis, T.R. Kress, M.J. Morelli et al. // Genome. Res. – 2017. –
V. 27. – P. 1658–1664.
132. Kelly, C.M. Using multiple targeted therapies in oncology: Considerations for use, and progress to date in breast cancer / C.M. Kelly, A.U. Buzdar // Drugs. – 2013. – V. 73. – P. 505-515.
133.Kim, J.S. Association of a common AGO1 variant with lung cancer risk: a twostage casecontrol study / G. Sun, J. Yan, K. Noltner et al. // Mol. Carcinog. - 2010. - V.
49.- P. 913–921.
134.Lebron-Zapata, L. Overview of breast cancer screening and diagnosis / L. Lebron-Zapata, M.S. Jochelson // PET. Clin. - 2018. - V. 13 (3). - P.301-323.
135.Lee Y.H.P., Eva Oncogenes and Tumor Suppressor Genes / Eva Y.H.P. Lee, William J. Muller // Cold. Spring. Harb Perspect. Biol. – 2010. – V. 2 (10). - a003236.
136.Luzzatto, L. Somatic mutations in cancer development / L. Luzzatto // Environ Health. - 2011. – V. 10. – Suppl. 1. – P. S12.
137.Malins, D.C. Major alterations in the nucleotide structure of DNA in cancer of the female breast / D.C. Malins, R. Haimanot // Cancer. Res. – 1991. – V. 51 (19). - P.
5430 5432.
138. McGranahan, N. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future / N. McGranahan, C. Swanton // Cell – 2017. – V. 168. – P. 613-628.
Рекомендовано к покупке и изучению сайтом МедУнивер - https://meduniver.com/